News | FDA

Top News

OPDP Issues Warning Letter Over Radio Ad

Full Article

September 16, 2020
HHS Blocks FDA From Requiring Premarket Review of Laboratory-Developed Tests Without Rulemaking

Full Article

September 2, 2020
FDA Issues Final Guidance on Civil Money Penalties for ClinicalTrials.gov Reporting Violations

Full Article

August 17, 2020
Indivior Agrees To Plead Guilty, Pay $600 Million as Part of Largest-Ever DOJ Settlement Involving an Opioid

Full Article

July 29, 2020
FDA To Use COVID-19 Risk Assessment System As It Restarts Domestic Inspections; Most Will Be Preannounced

Full Article

July 10, 2020

LATEST HEADLINES

OPDP Researchers To Examine Medical Conference Attendees’ Observations on Drug Promotion

September 20, 2020
Court Issues First Consent Decree of Permanent Injunction Stemming from FSMA Produce Safety Rule Violations

September 17, 2020
FSIS Proposes To Expand Categories of Products Eligible for Generic Label Approval

September 17, 2020
Guidance Explains How FDA Recognizes, Withdraws Voluntary Consensus Standards for Medical Devices

September 16, 2020
OPDP Issues Warning Letter Over Radio Ad

September 16, 2020
FDA Issues Guidance on Measuring and Analyzing Common COVID-19 Symptoms in Clinical Trials

September 16, 2020
Former Indivior Medical Director Pleads Guilty to Misbranding Charge Brought Under Park Doctrine

September 10, 2020
ACRO Publishes Manual and Toolkit for Conducting Decentralized Clinical Trials

September 9, 2020
Draft Guidance Offers Recommendations for Capturing Patient Perspectives When Developing, Evaluating Devices

September 9, 2020
Judge Grants Preliminary Injunction in Marketing Case

September 9, 2020

Latest FDA Intelligence

New Normal for Ad Promo Is Likely the Old Normal

September 11, 2020
Limitations of Promotional Claims on Facial Masks Marketed under Emergency Use Authorizations

September 9, 2020
FDA’s 'Intended Use' Saga

August 18, 2020
It’s More than a New Graphic: How the New Nutrition Facts Panel Can Impact a Food’s Labeling, Marketing and Formulation

August 11, 2020
Bad Ad Program At 10

July 27, 2020

NEWSLETTERS

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1600647455
            [c] => 1600647455
            [l] => 2000000
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1600647455
            [c] => 1600647455
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1600647455
            [c] => 1600647455
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1600647455
            [c] => 1600647455
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1600647455
            [c] => 1600647455
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Top News

OPDP Issues Warning Letter Over Radio Ad

HHS Blocks FDA From Requiring Premarket Review of Laboratory-Developed Tests Without Rulemaking

FDA Issues Final Guidance on Civil Money Penalties for ClinicalTrials.gov Reporting Violations

Indivior Agrees To Plead Guilty, Pay $600 Million as Part of Largest-Ever DOJ Settlement Involving an Opioid

FDA To Use COVID-19 Risk Assessment System As It Restarts Domestic Inspections; Most Will Be Preannounced

LATEST HEADLINES

Latest FDA Intelligence

New Normal for Ad Promo Is Likely the Old Normal

Limitations of Promotional Claims on Facial Masks Marketed under Emergency Use Authorizations

FDA’s 'Intended Use' Saga

It’s More than a New Graphic: How the New Nutrition Facts Panel Can Impact a Food’s Labeling, Marketing and Formulation

Bad Ad Program At 10

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT